XPENG Launches G9 SUV and P7 Sedan for Europe
3.2.2023 10:00:00 EET | Business Wire | Press release
XPENG (NYSE: XPEV and HKEX: 9868), today launched its two latest smart EV models for European markets: G9 flagship SUV, and the new P7 sports sedan. Both models, on show at eCar Expo in Stockholm Feb 3-5, are now available for order in Denmark, Norway, the Netherlands, and Sweden.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230202005580/en/
Premium electric smart sedan with sports car DNA (Photo: Business Wire)
“XPENG G9 and P7 bring a combination of superior styling, quality, performance and comfort, exemplifying our market-leading technology and innovation. Today also represents a significant milestone as we build our presence in Europe. We believe both vehicles deliver a new level of sophistication and a people-first mobility experience, and will be the electric vehicles of choice for many European customers,” said Brian Gu, Vice Chair and President of XPENG.
G9 features XPENG’s latest powertrain system, battery technology, and advanced driver assistance system (ADAS), fully complemented by a luxurious and immersive cabin experience. The new P7 - an upgraded version of P7 - combines its signature sports sedan profile with greater range, faster charging and a brand new smart cabin.
Faster Charging. Longer Range
XPENG’s new models bring some of the most powerful and advanced EV technology to Europe. XPENG G9 features a new powertrain system with 800 V Silicon Carbide (SiC) platform for ultra-fast charging of up to 300 kW, allowing drivers to add up to 100 km of range in just five minutes. This makes it possible to charge the 98 kWh battery from 10 % to 80% in just 20 minutes. G9 can travel up to 570 km WLTP on a single charge (RWD Long Range), exceptional for the battery size. G9 can be fitted with an electric tow bar, for up to 1,500 kg towed load, to suit European lifestyles.
The new P7 has been optimized with the maximum charging power of up to 175 kW, delivering fast charging from 10% to 80% in only 29 minutes. P7’s range has been improved, offering up to 576 km WLTP on a single charge (RWD Long Range). An electric tailgate and soft-closing doors are introduced for even greater comfort and convenience, along with a heat pump and heated steering wheel for more relaxing winter driving in the colder regions of Europe.
XPENG G9 and P7 are both engineered to meet E-NCAP five-star safety standards and stringent EU WVTA vehicle certification.
Superior Performance. Elegant Design
XPENG G9 and P7 boast superior performance with their advanced systems and elegant aerodynamic profiles, and are available in all-wheel-drive or rear-wheel drive configurations.
G9’s all-wheel drive version boasts up to 551 hp with a maximum torque of 717 Nm, powering acceleration from 0–100 km/h in just 3.9 seconds. The dual-chamber air spring system provides a wide range of stiffness adjustments to help the vehicle handle complex road conditions and ensure optimal ride comfort.
For the new P7, the all-wheel drive version accelerates from 0 to 100 km/h in just 4.1 seconds – outperforming even some sports car models. Brembo brakes also come as standard, giving drivers an extra level of control. All of this comes wrapped up in an exterior using XPENG's "Dynamic Aesthetics" design language that creates a more dynamic sports silhouette.
The new P7 is offered in a stunning range of colour styles, as well as an exclusive Wing Edition featuring scissors doors.
Both models adopt hidden door handles, with extremely low drag coefficients (0.236 for P7 and 0.272 for G9), for lower power consumption and extended range.
Comfort and Intelligence
The cabins of both vehicles use wraparound designs with high-quality finishing and materials to create a warm and comfortable environment. The ergonomically designed front seats feature heating and ventilation functions. To create an even more immersive cabin, both P7 and G9 can be configured with a Dynaudio sound system, producing up to 860 W and 2150 W respectively.
Both XPENG G9 and P7 come equipped with XPENG's proprietary Advanced Driver Assistance System, XPILOT, offering safety, driving, and parking support through a variety of smart functions. These functions are supported by 29 sensors including high-definition millimeter-wave radars, ultrasonic sensors, surround view and high perception cameras, enabling the vehicles to safely tackle multiple driving scenarios.
The upgraded in-car Xmart OS boasts a new 3D UI that supports English, Nederlands, Dansk, Norsk, and Svenska, depending on the market. Xmart OS also comes with the improved "Hey, XPENG" voice assistant, which can distinguish complex voice commands from all four zones of the cabin. These services are supported by wide infotainment screens and a library of in-car apps to assist, inform and entertain drivers and passengers.
G9 and P7 will also support easy and seamless over-the-air (OTA) updates that allow both software and firmware to be improved during normal use.
Expanding Service and Charging Networks
Delivery of the new models will capitalize on the opening of XPENG’s new Delivery and Service Centers in the key markets: at Lørenskog in Norway (opening February 2023), Badhoevedorp in the Netherlands, Stäket, Järfälla in Sweden and Hillerød in Denmark – all opening in the Q2 2023.
XPENG will also open additional authorized service locations with dedicated partners in key European countries by the end of 2023.
XPENG customers can access over 400,000 public charging stations in Europe, by collaboration with major European third-party charging operators and mobility service providers (Plugsurfing and Shell Recharge). With its new models, XPENG will provide third party home charger and installation services together with local partners, to offer customers a seamless easy charging experience.
Warranty
As a brand committed to product quality and offering better customer experiences, XPENG is proud to offer a five-year/120,000 km warranty* as standard for hassle-free ownership. For customers** ordering our new P7 sedan or G9 SUV between February 3 and December 31, 2023, the standard warranty will be extended to seven years/160,000 km from the date of delivery. This extended warranty is linked to the vehicle and is transferable when or if the vehicle is sold.
*For more information on the limited warranty policy, please refer to the warranty booklet.
**For more information on who is eligible for this extended warranty offer, please refer to the warranty booklet.
Pricing, Test Drive and Delivery
Expected starting prices* for the European version G9 are as follows
|
Model: |
XPENG G9 |
||
|
Version |
RWD Standard
|
RWD Long
|
AWD
|
|
Price(MSRP) - Norway (NOK) |
499 900 |
569 900 |
639 900 |
|
Price(MSRP) - Sweden (SEK) |
699 900 |
749 900 |
829 900 |
|
Price(MSRP) - Netherlands (EURO) |
57 990 |
61 990 |
71 990 |
|
Price(MSRP) - Denmark (DKK) |
479 900 |
549 900 |
599 900 |
Expected starting prices* for the new European version P7 are as follows
|
Model: |
XPENG P7 |
||
|
Version |
RWD Long Range |
AWD Performance |
Wing Edition |
|
Price(MSRP) - Norway (NOK) |
439 900 |
479 900 |
649 900 |
|
Price(MSRP) - Sweden (SEK) |
599 900 |
669 900 |
799 900 |
|
Price(MSRP) - Netherlands (EURO) |
49 990 |
59 990 |
69 990 |
|
Price(MSRP) - Denmark (DKK) |
399 900 |
479 900 |
599 900 |
*All prices include VAT and exclude local taxes, registration fees, and delivery costs. Please contact local XPENG representatives for details.
Deliveries for the new P7 will begin in June and G9 deliveries are expected to commence in September.
Customers can contact XPENG’s experience stores (Oslo, The Hague, Stockholm, Copenhagen) for test drive schedules. For more information about the G9 and P7, please visit the dedicated local XPENG websites:
https://heyxpeng.com/no/p7
https://heyxpeng.com/se/p7
https://heyxpeng.com/dk/p7
https://heyxpeng.com/nl/p7
https://heyxpeng.com/no/g9
https://heyxpeng.com/se/g9
https://heyxpeng.com/dk/g9
https://heyxpeng.com/nl/g9
Presskit (visual assets and specs) link
Follow us:
XPENG Twitter
XPENG LinkedIn
XPENG Facebook
XPENG Instagram
XPENG TikTok
XPENG YouTube
About XPeng Inc.
XPeng is a leading Chinese Smart EV company that designs, develops, manufactures, and markets Smart EVs that appeal to the large and growing base of technology-savvy middle-class consumers. Its mission is to drive Smart EV transformation with technology and data, shaping the mobility experience of the future. In order to optimize its customers’ mobility experience, XPeng develops in-house its full-stack advanced driver-assistance system technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrical/electronic architecture. XPeng is headquartered in Guangzhou, China. In 2021, the Company established its European headquarters in Amsterdam, along with other dedicated offices in Copenhagen, Munich, Oslo, and Stockholm. The Company’s Smart EVs are mainly manufactured at its plant in Zhaoqing, Guangdong province. For more information, please visit https://heyxpeng.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005580/en/
Contact information
For Media Enquiries:
Email: pr@xiaopeng.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
